Open AccessEfficacy and Tolerability of Dolutegravir-Based Dual-Therapies in HIV Naive and Switch Patients
Author(s) -
JM Vinuesa Hernando,
Galadriel Pellejero-Sagastizabal,
Mercedes Gimeno-Gracia,
Isabel Sanjoaquín-Conde,
María José Crusells-Canales,
Raquel Fresquet-Molina,
Raquel Gracia-Piquer
Publication year - 2022
Publication title -
journal of biomedical research and environmental sciences
Language(s) - English
Resource type - Journals
ISSN - 2766-2276
DOI - 10.37871/jbres1395
Subject(s) - tolerability , dolutegravir , medicine , antiretroviral therapy , human immunodeficiency virus (hiv) , oncology , pharmacology , adverse effect , viral load , virology
Objectives: The introduction of dual-therapy both as preferred starting therapy and in switches has been a revolution, allowing the same efficacy results to be obtained as therapies with more Active Ingredients (AI) with a lower risk of toxicity and interactions. The aim of the study is to analyze the efficacy, tolerability and reasons for switching patients to dolutegravir-based dual therapies.